MCET.US Multicell Techs Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 15, 2026
Market cap
USD 500K
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Aug 2015.

Is MCET.US undervalued?

Graham number

The Graham number of Multicell Techs Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Multicell Techs Inc fundamental analysis

No fundamental analysis for Multicell Techs Inc yet.

Multicell Techs Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Multicell Techs Inc

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent imm…

Full company profile